PEAR News and Press, Pear Therapeutics Inc. From 10/31/22

Pear Therapeutics, Inc. (the “Company”) (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it will issue its third quarter 2022 financial results after the close of mark...

Real-world observational analysis evaluating treatment of substance use disorder (SUD) with prescription digital therapeutics (PDTs) among a large, geographically diverse population Results demonstrate the benefit of PDTs for patients to access effective SUD treatment ...

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the LifeSci Partners HealthTech Symposium on September 20, 2022. Corey McCan...

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference taking place Sep...

Camille Griffin Graham Correctional Institution, a state prison for women in Columbia, S.C., i s the first in the nation to implement FDA-authorized PDTs in a correctional setting Collaboration delivers Pear’s reSET ® and reSET-O ® , for trea...

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in Citi’s 17th Annual BioPharma Conference taking place September 7-8 in...

Lots of payors are adding reSET to their covered benefit plans, and savings results far exceed prices of the products, usually leaving about 50% in surplus for the health system. Payor contract economics is making timing issues for revenue recognition, but run-rate revenue still indic...

Pear Therapeutics, Inc. (PEAR) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Meara Murphy - Senior Director of Corporate Communications Ronan O'Brien - General Counsel and Chief Compliance Officer Corey McCann - President and Ch...

Pear Therapeutics press release ( NASDAQ: PEAR ): Q2 GAAP EPS of $0.04 beats by $0.29 . Revenue of $3.3M (+175.0% Y/Y) misses by $0.94M . Shares -0.44% . For further details see: Pear Therapeutics GAAP EPS of $0.04 beats by $0.29, revenue of $3.3M...

20% quarter-over-quarter revenue growth to $3.3 million Recent real-world health economic data for all three of Pear’s commercial products show cost-savings 1-3 Recent commercial formulary additions for reSET® and reSET-O® Pear Ther...